Purchase this article with an account.
Young Ju Lew, Jung Jin Lee, Eun Jee Chung, Eun Hye Lim, Sung Won Cho, Chul Gu Kim, Tae Gon Lee; Incidence Of New Choroidal Neovascularization In Fellow Eyes Of Patients Treated With Amd In Korea. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3824.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the incidence of new neovascular age related macular degeneration in fellow eyes and the difference between the treatment of anti-VEGF and the subtype of age related macular degeneration.
Data of patients at Kim’s eye hospital diagnosed with one-eye age-related macular degeneration treated with anti-VEGF antibody from January 2009-August 2009 were retrospectively collected. All of the patients had more than 24 months follow up. The incidence rate evaluated at 12month and 24month. And the differences of incidence between the treatment of anti-VEGF and the subtype of age related macular degeneration were evaluated
Out of the 419 eyes reviewed, 105(25.1%) eyes were affected both eyes at first visit. New CNV developed in fellow eyes in 7.0% by 12 months and in 10.8% by 24 months. The conversion rate in the treatment with bevacizumab group (n=100) was 7.0% and 16.0% by 12 and 24 months. In the treatment with ranibizumab group (n=123), the conversion rate was 8.1% and 9.8% by 12 and 24months. In the mixed treatment group (n=91), 5.5% converted by 12 months and 24 months. In the subtype of AMD, fellow eyes in 5.1% of the predominant classic choroidal neovascularization group (n=99) converted by 12 months and fellow eyes in 9.1% converted by 24 months. The conversion rate in the occult/minimally classic choroidal neovascularization (n=130) group was 6.9% and 10.0% by 12 and 24 months, respectively. In the polypoidal choroidal neovascularization group, 9.4% converted by 12 months and 14.1% converted by 24 months.
In our study, new CNV developed in fellow eyes in 7.0 % by 12 months and 10.8% by 24 months. Differences in conversion rates at 12 and 24 months between the treatment groups and subtype of AMD were not statistically significant.
This PDF is available to Subscribers Only